Innovax-ND-ILT
Marek's disease vaccine, Newcastle disease vaccine & infectious laryngotracheitis vaccine (live recombinant)
Table of contents
Overview
Innovax-ND-ILT is a veterinary vaccine used to protect chickens against three separate infections, caused by Newcastle disease (ND) virus, avian infectious laryngotracheitis (ILT) virus and Marek’s disease (MD) virus.
ND is a viral infection of chickens which causes gasping and coughing, nervous signs (drooping wings, twisting of the head and neck, circling and paralysis), swelling of the tissues around the eyes and neck, greenish watery diarrhoea and reduced egg production.
MD is a herpesvirus infection of chickens which can cause paralysis of the wings and legs and causes tumours in various organs. Chickens become infected at an early age via inhalation of dander (flakes of skin) containing the virus which can remain infectious for several months after being shed from the body. Birds infected with MD virus can be carriers and shedders of the virus for life.
ILT virus infections can produce respiratory signs, decreased egg production, thin egg shells, lack of growth, neurological and ophthalmologic signs and death. Innovax-ND-ILT contains a live strain of turkey herpesvirus (strain HVT) which has been modified so that it will produce proteins from ND virus and ILT virus.
Authorisation details
Product details | |
---|---|
Name |
Innovax-ND-ILT
|
Agency product number |
EMEA/V/C/005190
|
Active substance |
Cell-associated live recombinant turkey herpesvirus (strain HVT/NDV/ILT) expressing the fusion protein of newcastle disease virus and the glycoproteins gD and gI of infectious laryngotracheitis virus
|
International non-proprietary name (INN) or common name |
Marek's disease vaccine, Newcastle disease vaccine & infectious laryngotracheitis vaccine (live recombinant)
|
Species |
|
Anatomical therapeutic chemical veterinary (ATCvet) codes |
QI01AD
|
Publication details | |
---|---|
Marketing-authorisation holder |
Intervet International B.V.
|
Revision |
1
|
Date of issue of marketing authorisation valid throughout the European Union |
16/09/2020
|
Contact address |
Wim de Körverstraat 35 |
Product information
18/03/2021 Innovax-ND-ILT - EMEA/V/C/005190 - IG/1348
This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.
Product information documents contain:
- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).
You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.
Pharmacotherapeutic group
Immunologicals for aves
Therapeutic indication
For active immunisation of one-day-old chicks or embryonated chicken eggs:
- to reduce mortality and clinical signs caused by Newcastle disease (ND) virus,
- to reduce mortality, clinical signs and lesions caused by avian infectious laryngotracheitis (ILT) virus and Marek’s disease (MD) virus.